Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020193715 - ADULT LIVER PROGENITOR CELLS FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE

Publication Number WO/2020/193715
Publication Date 01.10.2020
International Application No. PCT/EP2020/058587
International Filing Date 26.03.2020
IPC
C12N 5/0775 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
0775Mesenchymal stem cells; Adipose-tissue derived stem cells
C12N 5/071 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
A61K 35/407 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
37Digestive system
407Liver; Hepatocytes
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/727 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
727Heparin; Heparan
Applicants
  • PROMETHERA BIOSCIENCES S.A./N.V. [BE]/[BE]
Inventors
  • VEULEMANS, Nancy
  • BARTHEL, Virginie
  • SOKAL, Etienne
  • BELMONTE, Nathalie
Agents
  • BRANTSANDPATENTS BVBA
Priority Data
19165280.926.03.2019EP
19201348.003.10.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ADULT LIVER PROGENITOR CELLS FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE
(FR) CELLULES PROGÉNITRICES DU FOIE ADULTE POUR LE TRAITEMENT D'UNE STÉATOSE HÉPATIQUE NON ALCOOLIQUE
Abstract
(EN)
The invention relates to the use of a composition comprising adult human liver- derived progenitor cells, such as heterologous human adult liver-derived progenitor cells (HALPC), for the treatment of a patient having non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH), or wherein the patient is at risk of developing NASH. The treatment comprises a step of administering to said patient an amount of said composition which comprises a dose of 0.25 to 2.5 million said progenitor cells per kg body weight; wherein the composition is substantially free of an effective amount of an anticoagulant, and wherein the patient does not receive any co-treatment with an anticoagulant.
(FR)
L'invention concerne l'utilisation d'une composition comprenant des cellules progénitrices dérivées du foie humain adulte, telles que des cellules progénitrices dérivées du foie adulte humain hétérologues (HALPC), pour le traitement d'un patient ayant une stéatose hépatique non alcoolique (NAFLD), tel qu'une stéatose isolée non alcoolique (NAFL) ou une stéatohépatite non alcoolique (NASH), ou pour un patient présentant un risque de développer une NASH. Le traitement comprend une étape d'administration audit patient d'une quantité de ladite composition comprenant une dose de 0,25 à 2,5 millions desdites cellules progénitrices par kg de poids corporel; la composition étant sensiblement exempte d'une quantité efficace d'un anticoagulant, et le patient ne recevant pas de co-traitement avec un anticoagulant.
Latest bibliographic data on file with the International Bureau